NYU Departments of Medicine & Population Health, NYU Grossman School of Medicine, New York, New York, USA
Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Gut. 2023 Apr;72(4):663-670. doi: 10.1136/gutjnl-2022-327845. Epub 2023 Jan 9.
There is an increasing incidence of inflammatory bowel disease (IBD) for which environmental factors are suspected. Antibiotics have been associated with development of IBD in earlier generations, but their influence on IBD risk in adults is uncertain.
To assess the impact of antibiotic exposure, including dose-response, timing and antibiotic class, on the risk of IBD in all individuals aged ≥10 years.
Using Denmark nationwide registries, a population-based cohort of residents aged ≥10 years was established between 2000 and 2018. Incidence rate ratios (IRRs) for IBD following antibiotic exposure were calculated using Poisson regression.
There were a total of 6 104 245 individuals, resulting in 87 112 328 person-years of follow-up, and 52 898 new cases of IBD. Antibiotic exposure was associated with an increased risk of IBD as compared with no antibiotic exposure for all age groups, although was greatest among individuals aged 40-60 years and ≥60 years (age 10-40 years, IRR 1.28, 95% CI 1.25 to 1.32; age 40-60 years, IRR 1.48, 95% CI 1.43 to 1.54; age ≥60 years, IRR 1.47, 95% CI 1.42 to 1.53). For all age groups a positive dose-response was observed, with similar results seen for both ulcerative colitis and Crohn's disease. The highest risk of developing IBD was seen 1-2 years after antibiotic exposure, and after use of antibiotic classes often prescribed to treat gastrointestinal pathogens.
Antibiotic exposure is associated with an increased risk of IBD, and was highest among individuals aged 40 years and older. This risk increased with cumulative antibiotic exposure, with antibiotics targeting gastrointestinal pathogens and within 1-2 years after antibiotic exposure.
炎症性肠病(IBD)的发病率不断上升,其病因疑似与环境因素有关。抗生素曾被认为与上一代人的 IBD 发病相关,但它们对成年人 IBD 风险的影响尚不确定。
评估抗生素暴露(包括剂量反应、时间和抗生素类别)对所有≥10 岁人群 IBD 发病风险的影响。
利用丹麦全国性登记系统,于 2000 年至 2018 年建立了一个≥10 岁居民的基于人群的队列。采用泊松回归计算抗生素暴露后 IBD 的发病率比值(IRR)。
共纳入 6104245 名患者,随访 87112328 人年,发生 52898 例 IBD 新发病例。与未使用抗生素相比,所有年龄组的抗生素暴露均与 IBD 发病风险增加相关,不过在 40-60 岁和≥60 岁年龄组中相关性最强(10-40 岁年龄组,IRR 1.28,95%CI 1.25-1.32;40-60 岁年龄组,IRR 1.48,95%CI 1.43-1.54;≥60 岁年龄组,IRR 1.47,95%CI 1.42-1.53)。各年龄组均观察到了阳性剂量反应,溃疡性结肠炎和克罗恩病的结果相似。抗生素暴露后 1-2 年发生 IBD 的风险最高,并且与常用于治疗胃肠道病原体的抗生素类别相关。
抗生素暴露与 IBD 发病风险增加相关,在 40 岁及以上人群中风险最高。这种风险随着累积抗生素暴露量的增加而增加,与针对胃肠道病原体的抗生素和抗生素暴露后 1-2 年内有关。